Publicação

Use of Platelet rich plasma in persistent olfactory dysfunction after COVID-19: a prospective study

Ver documento

Detalhes bibliográficos
Resumo:Abstract Introduction: A promising technique to treat persistent olfactory impairment has recently been explored: platelet rich plasma (PRP) injection into the olfactory mucosa. Objectives: This study aimed to determine efficacy, safety, and feasibility of a new PRP injection protocol in treating persistent COVID-19 induced olfactory dysfunction (pCIOD). Material and Methods: Patients with pCIOD lasting for ≥ 12 months were enrolled. All patients had previously performed olfactory training and adjuvant therapy without achieving substantial improvement. Olfactory perception threshold (OPT) and visual analog scale (VAS) were measured at baseline, one month and three months after injection. Results: Twenty patients were enrolled. There was a significant change in OPT after injection (mean baseline OPT: 4.36 ± 1.6 versus 1-month after injection: 6.9 ± 2.6, p = 0.012 versus 3-months after injection: 7.2 ± 2.8, p =0.009). No severe complications were reported. Conclusions: Single-site PRP injection into the olfactory mucosa is a novel, safe and effective approach that may enhance olfactory recovery in pCIOD patients.
Autores principais:Sousa,Francisco Alves de
Outros Autores:Machado,André de Sousa; Costa,Joana Raquel; Correia,João Tavares; Castro,Afonso; Pinto,Ana Nóbrega; Silva,Ana; Santos,Mariline; Meireles,Luís
Assunto:olfactory dysfunction anosmia hyposmia platelet rich plasma single-site injection COVID-19
Ano:2023
País:Portugal
Tipo de documento:artigo
Tipo de acesso:acesso aberto
Instituição associada:Fundação para a Ciência e Tecnologia
Idioma:inglês
Origem:SciELO Portugal
Descrição
Resumo:Abstract Introduction: A promising technique to treat persistent olfactory impairment has recently been explored: platelet rich plasma (PRP) injection into the olfactory mucosa. Objectives: This study aimed to determine efficacy, safety, and feasibility of a new PRP injection protocol in treating persistent COVID-19 induced olfactory dysfunction (pCIOD). Material and Methods: Patients with pCIOD lasting for ≥ 12 months were enrolled. All patients had previously performed olfactory training and adjuvant therapy without achieving substantial improvement. Olfactory perception threshold (OPT) and visual analog scale (VAS) were measured at baseline, one month and three months after injection. Results: Twenty patients were enrolled. There was a significant change in OPT after injection (mean baseline OPT: 4.36 ± 1.6 versus 1-month after injection: 6.9 ± 2.6, p = 0.012 versus 3-months after injection: 7.2 ± 2.8, p =0.009). No severe complications were reported. Conclusions: Single-site PRP injection into the olfactory mucosa is a novel, safe and effective approach that may enhance olfactory recovery in pCIOD patients.